Furthermore, BiP depletion sensitized GBM samples to treatment with chemotherapeutics, such as 5-fluorouracil (5-FU), highlighting a novel mechanism for targeting specific UPR arms towards GBM therapy (Figure 2) [139]. This evidence concerns the gene HSPA5 and glioblastoma.